NFKB1 and Parkinson disease: Modulating or inhibiting the NF-κB pathway using compounds such as hypoestoxide and lenalidomide has shown efficacy in reducing microgliosis, protecting dopaminergic neurons, and alleviating motor deficits in PD models [115,116].